Trial Profile
Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Iodiopathic Choroidal Neovascularization in Young Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- Acronyms INTUITION
- 01 Feb 2022 Primary endpoint (Mean change in best-corrected visual acuity (BCVA) expressed as number of letters gained or lost measured with Early Treatment Diabetic Retinopathy Study (ETDRS) scale from baseline to week 52) has been met, according to Results published in the Retina.
- 01 Feb 2022 Results published in the Retina
- 22 Jul 2019 Status changed from active, no longer recruiting to completed.